Mainz Biomed Partners with OncoVanguard8 for ColoAlert Expansion in South America

Mainz Biomed N.V., a molecular genetics diagnostic firm, has announced a strategic agreement with OncoVanguard8 to introduce ColoAlert, a colorectal cancer screening test, to South America. The collaboration will initially focus on Peru, with plans to extend to Colombia and Ecuador. OncoVanguard8, based in Lima, is known for providing advanced healthcare products in these regions.

Colorectal cancer is prevalent yet preventable, with approximately 17,000 new cases annually in the three targeted countries. The initiative aims to enhance early detection through DNA-based testing, potentially increasing participation in cancer screening programs and aligning with public health objectives to reduce mortality.

The agreement includes plans for a final distribution strategy to be finalized soon. This development signifies a significant advancement in making innovative diagnostic solutions available in Latin America.